Back

Reducing the burden of advanced heart failure: a clinical and economical analysis of an intermittent Levosimendan programme

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Towards optimisation of heart failure therapies Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Daniel Filipe Inacio Cazeiro

Hospital Santa Maria, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
Beta-blockers in patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: cardiovascular and respiratory outcomes
Doctor B. Beer (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Short-chain fatty acids, sodium-glucose cotransporter type 2 inhibitors, and cardiovascular benefit: a possible relationship?
Doctor M. Cortes Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Age- and sex-related differences in heart failure characteristics and treatment patterns across the ejection fraction spectrum
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience
Doctor N. Bonini (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Sequencing, intensity, and discontinuation of guideline-directed medical therapy after heart failure hospitalisation in the United States: results from the EMPACE study
Professor A. Alhamdow (DE)
Abstract Slides Video

Access the full session

Session thumbnail
Towards optimisation of heart failure therapies

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Real-world impact of intermittent levosimendan on survival, hospitalizations, and healthcare costs in advanced heart failure
thumbnail
Congress Presentation
The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?
thumbnail
Congress Presentation
The experience of more than three hundred levosimendan administrations: what we have learned

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources